Related Experiment Video
Updated: Oct 25, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors
Milica Vucetic1, Boutaina Daher1, Shamir Cassim1
1Department of Medical Biology, Centre Scientifique de Monaco (CSM), MC, Monaco.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers with a dismal 5-year survival rate of 5% and very limited efficacy of the current therapeutic regimens. The lethality of PDAC stems from asymptomatic early stage of the disease, its propensity to rapidly disseminate, as well as unusual, dense and highly active surrounding stroma. Fortunately, promising literature data suggests that exploiting newly contextualized type of cell death, termed "ferroptosis", has great potential for overcoming the major problems regarding PDAC treatment. A major player in this type of cell death is Glutamate/Cystine antiporter - xCT, which is responsible for the uptake of oxidized form of cysteine, and thus maintenance of intracellular amino acid and redox homeostasis. xCT seems to fulfill all requirements of the solid and specific molecular target for ferroptosis-based anti-cancer therapy. In this chapter we summarized mounting literature data supporting this hypothesis, but also, we pointed out some of the underexamined aspects of xCT-dependent (patho)physiology of the cancer cell, which have to be addressed in future studies. The abstract could be used as "informative abstract" for the online version.
Insights
Pancreatic cancer (PDAC) is deadly, but targeting cell death via the Glutamate/Cystine antiporter (xCT) shows promise. Exploiting xCT may offer new therapeutic strategies for this aggressive cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with poor prognosis.
- Current treatments for PDAC have limited efficacy due to late diagnosis, rapid metastasis, and a dense tumor stroma.
- Ferroptosis, a newly defined form of cell death, presents a promising avenue for novel PDAC therapies.
Purpose of the Study:
- To review literature supporting the role of ferroptosis in PDAC treatment.
- To highlight the Glutamate/Cystine antiporter (xCT) as a key mediator of ferroptosis and a potential therapeutic target.
- To identify underexplored aspects of xCT-dependent physiology in cancer for future research.
Main Methods:
- Literature review and synthesis of existing research data.
- Analysis of the role of xCT in cellular homeostasis and cancer progression.
- Identification of xCT as a molecular target for ferroptosis-based cancer therapy.
Main Results:
- The Glutamate/Cystine antiporter (xCT) is crucial for maintaining intracellular amino acid and redox balance.
- xCT is implicated in ferroptosis, a cell death pathway with therapeutic potential against PDAC.
- Evidence suggests xCT is a viable and specific molecular target for anti-cancer strategies.
Conclusions:
- Targeting xCT-mediated ferroptosis offers a promising strategy to overcome therapeutic challenges in PDAC.
- Further investigation into the xCT-dependent pathophysiology of cancer cells is necessary.
- Exploiting ferroptosis represents a potential breakthrough in treating aggressive pancreatic cancer.
